Similarly, in ICI treatment, high CRP levels before treatment are associated with poor prognosis in cancer patients [20–24], whereas elevated CRP levels within 1 week after ICI initiation predict favourable treatment efficacy and prognosis in patients with non-small cell lung cancer [25]. The gene discussed is CRP; the disease is cancer.